Emulsion formulations
A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.
1. A pharmaceutical composition comprising:
a) from 10 to 25% by weight of solubilized testosterone undecanoate;
b) from 10 to 37.5% by weight of hydrogenated castor oil ethoxylate;
c) from 10 to 60% by weight of lipophilic surfactant selected from the group consisting of octanoic acid, decanoic acid, undecanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, propylene glycol monolaurate, glycerol/glyceryl monolinoleate, glyceryl mono-and dicaprylocaprate, or a combination thereof;
d) from 5 to 37.5% by weight of one or more phytosterol esters; and
e) 0-10% by weight of dl-alpha-tocopherol,
wherein the composition is a self-emulsifying oral formulation.
2. The pharmaceutical composition of claim 1 , comprising:
a) about 18.2% by weight of solubilized testosterone undecanoate;
b) about 15.0% by weight of hydrogenated castor oil ethoxylate;
c) about 39.9% by weight of propylene glycol monolaurate;
d) about 25.0% by weight of one or more phytosterol esters; and
e) about 2.0% by weight of dl-alpha-tocopherol,
wherein the composition is a self-emulsifying oral formulation.
3. A method of treating male hypogonadism in a male subject in need thereof, the method comprising administering the pharmaceutical composition of claim 1 to the subject.
4. The pharmaceutical composition of claim 1 , comprising 10 to 15% by weight of hydrogenated castor oil ethoxylate.
5. The pharmaceutical composition of claim 1 , wherein the lipophilic surfactant is propylene glycol monolaurate.
6. The pharmaceutical composition of claim 1 , comprising 10 to 25% by weight of the one or more phytosterol esters.
7. The pharmaceutical composition of claim 1 , comprising 0 to 5% by weight of dl-alpha-tocopherol.
8. The pharmaceutical composition of claim 7 , comprising from 10 to 15% by weight of hydrogenated castor oil ethoxylate.
9. The pharmaceutical composition of claim 8 , comprising from 15 to 55% by weight of propylene glycol monolaurate.